Publications by authors named "Erlewyn-Lajeunesse M"

Article Synopsis
  • * A survey conducted across 56 European countries revealed that while many pediatricians are aware of allergy guidelines, only a small percentage are familiar with specific allergy competencies from the EAACI.
  • * Access to allergy investigations and treatment varies among practitioners, with the main barriers to referrals being the belief that conditions can be managed within their facilities, despite many recognizing the need for specialist assessment.
View Article and Find Full Text PDF

The objective of the present study is to assess the rates of acquired tolerance to cow's milk (CM) after 36 months in subjects who consumed amino acid-based formula with synbiotics (AAF-S) or amino acid-based formula without synbiotics (AAF) during a 1-year intervention period in early life as part of the PRESTO study (Netherlands Trial Register number NTR3725). Differences in CM tolerance development between groups were analysed using a logistic regression model. Results show that the proportion of subjects (mean [±SD] age, 3.

View Article and Find Full Text PDF
Article Synopsis
  • Cow milk (CM) allergy is a common issue in young children, but current diagnostic methods are often unreliable or risky.
  • This study aimed to identify specific characteristics of T cells in CM-allergic patients that could serve as a new diagnostic marker.
  • The researchers found significant differences in the quantity and behavior of CM-specific T cells in allergic patients, leading to the development of a flow-cytometry assay that could help with diagnosing CM allergy more effectively.
View Article and Find Full Text PDF

Background: No approved treatment for peanut allergy exists for children younger than 4 years of age, and the efficacy and safety of epicutaneous immunotherapy with a peanut patch in toddlers with peanut allergy are unknown.

Methods: We conducted this phase 3, multicenter, double-blind, randomized, placebo-controlled trial involving children 1 to 3 years of age with peanut allergy confirmed by a double-blind, placebo-controlled food challenge. Patients who had an eliciting dose (the dose necessary to elicit an allergic reaction) of 300 mg or less of peanut protein were assigned in a 2:1 ratio to receive epicutaneous immunotherapy delivered by means of a peanut patch (intervention group) or to receive placebo administered daily for 12 months.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to identify factors predicting delayed gastric emptying (DGE) in children and assess their response to treatment over time.
  • It involved analyzing data from 285 children aged 0 to 18, focusing on symptoms, medical history, and outcomes over a 2-year follow-up period.
  • Key findings indicated that prior abdominal surgery significantly predicted DGE, and most children experienced a notable improvement in symptoms and reduced medication usage after two years.
View Article and Find Full Text PDF

This guideline advises on the management of patients with egg allergy. Most commonly egg allergy presents in infancy, with a prevalence of approximately 2% in children and 0.1% in adults.

View Article and Find Full Text PDF

Background: Food protein-induced enterocolitis syndrome (FPIES) is a delayed type of food allergy, most often seen in infancy. We aimed to estimate its incidence, to describe common food triggers and the patient journeys of this rare but serious condition.

Design: We undertook a prospective epidemiological survey of FPIES using the British Paediatric Surveillance Unit.

View Article and Find Full Text PDF

Background: Tolerance development is an important clinical outcome for infants with cow's milk allergy.

Objective: This multicenter, prospective, randomized, double-blind, controlled clinical study (NTR3725) evaluated tolerance development to cow's milk (CM) and safety of an amino acid-based formula (AAF) including synbiotics (AAF-S) comprising prebiotic oligosaccharides (oligofructose, inulin) and probiotic Bifidobacterium breve M-16V in infants with confirmed IgE-mediated CM allergy.

Methods: Subjects aged ≤13 months with IgE-mediated CM allergy were randomized to receive AAF-S (n = 80) or AAF (n = 89) for 12 months.

View Article and Find Full Text PDF

Background: Anaphylaxis is a severe, systemic hypersensitivity reaction that can be potentially life-threatening. Anaphylaxis during oral food challenge is not uncommon and can usually be effectively managed with intramuscular adrenaline as first line treatment. Although very rare, fatal anaphylaxis during in-hospital food challenge has been reported.

View Article and Find Full Text PDF
Article Synopsis
  • The ARTEMIS trial investigated the efficacy of AR101, an experimental oral biologic drug, to treat peanut allergies in children and adolescents aged 4-17 who experienced severe allergic reactions to peanuts.* -
  • This multicentre, double-blind, placebo-controlled study involved 18 hospitals across Europe and aimed to determine if participants could safely consume a higher dose of peanuts after 9 months of treatment compared to those given a placebo.* -
  • The trial also assessed safety by monitoring adverse events and examined the impact of treatment on the participants' quality of life related to food allergies using specific questionnaires.*
View Article and Find Full Text PDF

The EATERS mnemonic is a novel method for taking an allergy focused clinical history. It provides a degree of certainty for diagnosing food allergy and can be used in both IgE and non IgE mediated reactions. EATERS will allow health care professionals to use their existing clinical skills to interpret the history of an allergic reaction, and by doing so will help to make sense of allergy test results.

View Article and Find Full Text PDF

Background: Peanut allergy is classically managed by food avoidance. Immunotherapy programs are available at some academic centers for selected patients reacting to small amounts of peanut during food challenge. We aimed to determine and compare reaction thresholds and prevalence of anaphylaxis during peanut oral challenges at multiple specialist allergy centers.

View Article and Find Full Text PDF

Background: The prevalence and time trends of food allergy change during childhood depending on the age of the child and the type of food.

Objective: To study prevalence and longitudinal trends in food allergy from birth to 18 years in an unselected birth cohort in the Isle of Wight.

Method: Information on food allergy was collected at ages 1, 2, 4, 10 and 18 years from the Isle of Wight Birth Cohort (n = 1456).

View Article and Find Full Text PDF

Background: Previous reports have demonstrated the utility of T-cell proliferation and cytokine release assays as in vitro diagnostic tests for drug causation in drug hypersensitivity reactions (DHR). However, data from pediatric populations are scarce compared with data in adults.

Objective: To compare the lymphocyte proliferation assay (LPA) with combination cytokine assays in the pediatric population and to identify its potential use in the acute and postrecovery phases.

View Article and Find Full Text PDF

Study Question: How safe is live attenuated influenza vaccine (LAIV), which contains egg protein, in young people with egg allergy?

Methods: In this open label, phase IV intervention study, 779 young people (2-18 years) with egg allergy were recruited from 30 UK allergy centres and immunised with LAIV. The cohort included 270 (34.7%) young people with previous anaphylaxis to egg, of whom 157 (20.

View Article and Find Full Text PDF

Background: Live attenuated influenza vaccine (LAIV) is an intranasal vaccine recently incorporated into the United Kingdom immunization schedule. However, it contains egg protein and, in the absence of safety data, is contraindicated in patients with egg allergy. Furthermore, North American guidelines recommend against its use in asthmatic children.

View Article and Find Full Text PDF